Stemline Therapeutics Inc (NASDAQ:STML) had its buy rating reaffirmed by analysts at Roth Capital. Stemline Therapeutics Inc (NASDAQ:STML) weekly performance is -9.48%. On last trading day company shares ended up $12.89. Analysts mean target price for the company is $57.00. Stemline Therapeutics Inc (NASDAQ:STML) distance from 50-day simple moving average (SMA50) is -30.38%.
On May 1, 2014, SIGA Technologies, Inc. (NASDAQ:SIGA) reported its financial results for the quarter ended March 31, 2014. Revenue for the three months ended March 31, 2014 was $549,000, compared to $1.3 million in the first quarter of 2013, and the operating loss for the quarter was $5.6 million, compared to $5.8 million for the comparable quarter last year. Net loss per share, which included a $2.2 million income tax benefit, was $0.06 for the three months ended March 31, 2014. In comparison, net loss per share, which included a $2.3 million income tax benefit, was $0.09 for the three months ended March 31, 2013. SIGA Technologies, Inc. (NASDAQ:SIGA) shares advanced 0.75% in last trading session and ended the day on $2.68. SIGA return on assets is -10.40%. SIGA Technologies, Inc. (NASDAQ:SIGA) quarterly performance is -20.24%.
Trevena Inc (NASDAQ:TRVN) announced the appointment of John M. Limongelli, Esq., to the newly created position of Senior Vice President, General Counsel & Corporate Secretary, effective immediately. Trevena Inc (NASDAQ:TRVN) shares moved down -7.08% in last trading session and was closed at $4.46, while trading in range of $4.41 – $4.78. Trevena Inc (NASDAQ:TRVN) year to date (YTD) performance is -31.38%.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), reported its financial results for the quarter ended March 31, 2014. These results are discussed in Galmed’s Form 6-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2014, which includes Galmed’s unaudited condensed consolidated financial statements for the three months ended March 31, 2014, together with related and certain other information. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) ended the last trading day at $6.45. Company weekly volatility is calculated as 4.64% and price to cash ratio as 715.95. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) showed a negative weekly performance of -7.99%.
Leave a Reply